Join Now

Utah Life Sciences News & Events

PhotoPharmics Stay-At-Home Trial for People with Parkinson’s

July 17, 2020

This week, PhotoPharmics announced a collaboration with the Center for Health + Technology (CHeT) at the University of Rochester Medical Center to conduct an at home, telemedicine, phase 3 trial for the company’s Celeste® – a non-invasive, specialized light therapy device for Parkinson’s. The trial follows an FDA Breakthrough Device Designation for the device in April 2020.

Participants will use Celeste daily while enjoying typical activities, such as watching TV, eating, reading, or using a computer. “Our first trial showed improvement in quality of life on top of best managed care,” said Dan Adams, Science Officer at PhotoPharmics. “In addition to motor function, the Celeste trial aims to address the wide-spread, critical unmet needs associated with non-motor function, such as sleep, fatigue, depression, anxiety, and cognition. No current therapy addresses general non-motor function, which can be more debilitating than motor function, and eventually may be the cause for institutionalization.”

The trial is open to patients across the country and all clinical interactions between participants and researchers will be completed via teleconference so patients will not be required to travel.

“This is a significant development for PhotoPharmics’ innovative technology,” said Kelvyn Cullimore, president and CEO of BioUtah. “Because participants will remain in the home setting, the trial poses little risk for COVID-19, but offers tremendous upside for patients.”

Additional trial details can be reviewed at Clinicaltrials.gov (#NCT04453033).